Anika Therapeutics (ANIK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of three Class III Directors: Gary P. Fischetti, John B. Henneman III, and Stephen D. Griffin, all recommended by the board.
Ratification of Deloitte & Touche LLP as independent registered accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Approval sought for amendments to the 2017 Omnibus Incentive Plan and the 2021 Employee Stock Purchase Plan.
Other business may be addressed as appropriate at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election to Class III positions.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation is on the agenda.
Amendments to incentive and employee stock purchase plans are proposed for approval.
Latest events from Anika Therapeutics
- Revenue up 13% with margin expansion and strong adjusted EBITDA; guidance reaffirmed.ANIK
Q1 202630 Apr 2026 - Shareholders to vote on director elections, auditor, compensation, and equity plan amendments.ANIK
Proxy filing28 Apr 2026 - HA-based innovation and commercial growth fuel market expansion and a positive outlook through 2027.ANIK
2026 CG Musculoskeletal Conference2 Mar 2026 - 2026 revenue is guided up 1–9%, led by double-digit commercial channel growth and operational gains.ANIK
Q4 202526 Feb 2026 - Q2 revenue fell 5% as international OA Pain and new products offset U.S. softness.ANIK
Q2 20242 Feb 2026 - Integrity and Hyalofast fuel regenerative growth, supported by strong OA pain business and capital discipline.ANIK
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 revenue down 7% as focus shifts to high-growth HA and Regenerative Solutions.ANIK
Q3 202417 Jan 2026 - Growth in OA pain and regenerative products, with Cingal and Hyalofast targeting $1B+ U.S. markets.ANIK
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Refocused on core HA products, with Integrity and Hyalofast set to drive future growth.ANIK
The Sidoti Small-Cap Virtual Investor Conference11 Jan 2026